Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01069510 · ClinicalTrials.gov registry record · Phase 2
Spironolactone in Adult Congenital Heart Disease
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01069510 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 40 participants.
The verdict
NCT01069510, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function. Subjects from the study titled "Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" who have evidence of heart dysfunction and/or evidence of fibrosis (stiffening) in the heart muscle will be asked to take part in this study.
Interventions
- OTHER Placebo
- DRUG Spironolactone 25mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-02 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01069510
The ClinicalTrials.gov registry entry for NCT01069510 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01069510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01069510 about?
NCT01069510 is a clinical study titled "Spironolactone in Adult Congenital Heart Disease". The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function. Subjects from the study titled "Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" who have evidence of heart dysfunct...
What is the current status of trial NCT01069510?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2010-02. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01069510?
The interventions under investigation include: Placebo (OTHER), Spironolactone 25mg (DRUG).
Who is sponsoring clinical trial NCT01069510?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.